SCHEMBL4872319

SCHEMBL4872319

Nc1nc(O)c2[nH]ccc2n1

nearest known ligand 0.46

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 1/20 0.33
▸ REN P00797 1/20 0.32
▸ DCPS Q96C86 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ RIPK1 Q13546 1/20 0.31
▸ PDPK1 O15530 1/20 0.31
▸ PIK3CA P42336 2/20 0.30
▸ MTOR P42345 2/20 0.30
▸ DHFR P00374 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4840039 0.79 DYRK1A (0.35) DYRK1AMAPK1RIPK1PIK3CAMTOR
SCHEMBL29421618 0.79 PDPK1 (0.44) DYRK1ARENDCPSPDPK1DHFR
SCHEMBL17223741 0.79 PDPK1 (0.44) DYRK1ARENDCPSPDPK1DHFR
SCHEMBL18711719 0.78 KDR (0.45) DYRK1AMAPK1RIPK1PIK3CAMTOR
SCHEMBL23889230 0.76 DYRK1A (0.33) DYRK1ARENDCPSMAPK1RIPK1
SCHEMBL4106056 0.76 DYRK1A (0.50) DYRK1ARIPK1
SCHEMBL4838737 0.76 DYRK1A (0.41) DYRK1AMAPK1RIPK1PIK3CAMTOR
SCHEMBL21727172 0.76 DYRK1A (0.31) DYRK1AREN
SCHEMBL18194317 0.72 CHUK (0.40) RENDHFR
SCHEMBL20274839 0.72 REN (0.41) DYRK1ARENDCPSMAPK1PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7390890-B2 Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2008-06-24 — — US disclosed
CN-100393722-C Inhibitors of nucleoside metabolism EINSTEIN COLL MED (US) 2008-06-11 — — CN disclosed
US-20070197561-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2007-08-23 — — US disclosed
WO-2007069924-A1 DEAZAPURINE ANALOGS OF 4'-AZA-L-NUCLEOSIDES INDUSTRIAL RESEARCH LIMITED (NZ) 2007-06-21 — — WO disclosed
US-7211653-B2 Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2007-05-01 — — US disclosed
CN-1757646-A Inhibitors of nucleoside metabolism EINSTEIN COLL MED (US) 2006-04-12 — — CN disclosed
CN-1220695-C Inhibitors of nucleoside metabolism ALBERT EINSTEIN MEDICAL COLLAG (US) 2005-09-28 — — CN disclosed
EP-1023308-B1 INHIBITORS OF NUCLEOSIDE METABOLISM EINSTEIN COLL MED (US) 2005-09-07 — — EP disclosed
US-20050026936-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2005-02-03 — — US disclosed
US-6803455-B2 PYRROLO(3,2-D)PYRIMIDIN-7-YL)-1,4-IMINO-D-RIBITOL DERIVATIVES; FOR SUPPRESSION OF T-CELL FUNCTION ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY 2004-10-12 — — US disclosed
US-20030096830-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2003-05-22 — — US disclosed
US-6492347-B2 TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY 2002-12-10 — — US disclosed
US-20020061898-A1 Inhibitors of nucleoside metabolism BIOCRYST PHARMACEUTICALS, INC. 2002-05-23 — — US disclosed
US-6228847-B1 ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR ALBERT EINSTEIN COLLEGE OF MEDICINE 2001-05-08 — — US disclosed
CN-1279686-A Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLAGE OF MED (US) 2001-01-10 — — CN disclosed
US-6066722-A Inhibitors of nucleoside metabolism ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2000-05-23 — — US disclosed
US-5985848-A EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 1999-11-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026936-A1 Inhibitors of nucleoside metabolism CFH, CBR3, SLCO2B1 DYRK1A 1535/4885REN 708/4885DCPS 2509/4885
US-20020061898-A1 Inhibitors of nucleoside metabolism PNP, APRT, NUDT14 DYRK1A 2620/4885REN 1844/4885DCPS 186/4885
US-20070197561-A1 Inhibitors of nucleoside metabolism CFH, CBR3, SLCO2B1 DYRK1A 1535/4885REN 708/4885DCPS 2509/4885
US-20030096830-A1 Inhibitors of nucleoside metabolism CFH, NADK, UGT1A3 DYRK1A 1576/4885REN 602/4885DCPS 2518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback